Yüklüyor......

Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

BACKGROUND: Patients with primary focal segmental glomerulosclerosis (FSGS) resistant to current treatment regimens are at high risk of progression to end stage kidney disease. Antifibrotic agents, such as tumor necrosis factor α (TNF-α) antagonists, are a promising strategy to slow or halt the decl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Joy, Melanie S., Gipson, Debbie S., Powell, Leslie, MacHardy, Jacqueline, Jennette, J. Charles, Vento, Suzanne, Pan, Cynthia, Savin, Virginia, Eddy, Allison, Fogo, Agnes B., Kopp, Jeffrey B., Cattran, Daniel, Trachtman, Howard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2804955/
https://ncbi.nlm.nih.gov/pubmed/19932542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.ajkd.2009.08.019
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!